Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Business Development & Partnering Team are delighted to announce that the AIMday in Advanced Therapies & Regenerative Medicine is now open for registration by academics.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? 

If you answer YES to any of the above, now is the time to register for the AIMday in Advanced Therapies & Regenerative Medicine, taking place on Wednesday 3 April at the Blavatnik School of Government. A range of companies including LIft Biosciences, Alcyomics, Oxford MEStar, Novo Nordisk, DJS Antibodies, The Electrospinning Company and Bio-Techne are registered to attend, and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions. To see the questions posed by these companies, please visit aimday.se/atrm-2019/questions-listing.

This years AIMday follows on from previous successful AIMdays in Ageing (2016), Microscopy (2017) and Biomedical Imaging (2018).

FREE registration for academics is now open and closes on 15 March. 

Please note, advance registration is essential

To register and find out more, please visit aimday.se/ATRM-2019

What are AIMdays?

  • AIMdays provide a platform for companies to host roundtable discussions with a group of self-selecting academics
  • Industry sets the agenda and topics for discussion
  • Academics from across multiple disciplines sign up to participate in the discussions

How does it work?

Step 1: Companies submit a question/s around the theme of the day

Step 2: Oxford’s researchers sign up to answer one or more of the questions

Step 3: One question, one hour for discussion, one group of experts

 

For additional information please contact amira.burshan@medsci.ox.ac.uk

Find out more about the work of the Business Development & Partnering Team

Similar stories

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.

Com-COV vaccine mix-and-match study expands to 12-to-16-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a new study of COVID-19 vaccination schedules in young people aged 12 to 16.